Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 Universal CAR-T Cells for CD19+ B Cell Hematologic Malignancies
NCT04264039Phase 1Unknown
- Sponsor
- Xinqiao Hospital
- Start
- Apr 2020
- Primary completion
- Apr 2021
- Countries
- 1
01
Overview
Phase 1, open-label trial of Anti-CD19 UCAR-T cells in B cell acute lymphoblastic leukemia (B-ALL) and B cell lymphoma, sponsored by Xinqiao Hospital. Primary endpoint: Anti-tumor efficiency at 4 weeks. Status: unknown.
02
Drugs
Anti-CD19 UCAR-T cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B cell lymphoma
Beyond the preview
Go deeper on NCT04264039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04264039.